Provided by Tiger Trade Technology Pte. Ltd.

Novartis AG

135.43
+0.40000.30%
Volume:790.15K
Turnover:107.02M
Market Cap:262.17B
PE:18.55
High:135.69
Open:135.19
Low:135.03
Close:135.03
52wk High:137.40
52wk Low:96.06
Shares:1.94B
Float Shares:1.84B
Volume Ratio:1.06
T/O Rate:0.04%
Dividend:3.86
Dividend Rate:2.85%
EPS(TTM):7.30
EPS(LYR):5.92
ROE:32.62%
ROA:12.13%
PB:5.91
PE(LYR):22.89

Loading ...

Novartis Says Won't be Impacted by 100% Tariff on Branded Pharmaceutical Products

MT Newswires Live
·
Sep 26

U.S. Tariffs Pose Limited Risk to Big Swiss Pharma Groups -- Market Talk

Dow Jones
·
Sep 26

Novartis AG (NVS.US) CD20-Targeting Therapy Maintains High Efficacy for Up to 7 Years with Patient Self-Injection Option

Stock News
·
Sep 26

Eli Lilly Stock Is Trading Down Thursday: What's Behind The Move?

Benzinga_recent_news
·
Sep 26

Novartis increased its stockpiles of pharmaceuticals in the U.S., Reuters says

TIPRANKS
·
Sep 22

Novartis looking into price cut proposals for U.S., Bloomberg reports

TIPRANKS
·
Sep 22

Novartis AG CEO Says Company Studying Price Reduction Plans for US Market, Maintains Revenue Growth Outlook

Deep News
·
Sep 20

Novartis Signs Licensing Deal Worth Up to $5.7 Billion with Monte Rosa Therapeutics

Deep News
·
Sep 15

Novartis Shares Fall After Goldman Sachs Downgrade

MT Newswires Live
·
Sep 13

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

Dow Jones
·
Sep 13

Novartis (NVS) was downgraded to a Sell Rating at Goldman Sachs

TIPRANKS
·
Sep 12

Goldman Sachs Downgrades Novartis to Sell From Neutral, Adjusts Price Target to $118 From $119

MT Newswires Live
·
Sep 12

Novartis Cut to Sell From Neutral by Goldman Sachs

Dow Jones
·
Sep 12

Goldman Sachs Downgrades Novartis AG (NVS.US) to "Sell" Amid Generic Competition and Questioned Growth Narrative

Stock News
·
Sep 12

Novartis AG Rises Thursday, Outperforms Market

Dow Jones
·
Sep 12

Top Premarket Gainers

MT Newswires Live
·
Sep 09

Why JPMorgan is warning the Fed rate cut everyone expects could sink stocks

Dow Jones
·
Sep 09

Novartis to buy U.S. biotech in latest deal targeting firms in $1 billion to $3 billion range

Dow Jones
·
Sep 09

Novartis to Acquire Tourmaline Bio in Deal Valuing It at $1.4 Billion

Reuters
·
Sep 09

Novartis AG Falls Monday, Underperforms Market

Dow Jones
·
Sep 09